ABSTRACT

Angiotensin Receptor Blockers (ARBs) and calcium channel blockers (CCBs) are commonly prescribed antihypertensive agents in post menopausal women (PMW). However, the cost effectiveness of these drugs in alone has not been examined before in India. Therefore, the aim of this study was to evaluate the cost-effectiveness of Telmisartan versus amlodipine in the management of hypertension among hypertensive postmenopausal women. A prospective observational study was conducted in Department of General Medicine at Karuna Medical College Hospital, Palakkad for a period of October 2019 to September 2020. PMW with self reported cessation of menstruation for >12 consecutive months with or without co morbid diseases, newly diagnosed and treated for hypertension were included. These two drugs were found to be equieffective in reducing the blood pressure to the target goal, but the cost of reducing 1 mm of Hg systolic blood pressure (SBP) reduction was found to be 68.93 INR and 37.81 INR and distolic blood pressure (DBP) reduction with 106.57 INR and 76.58 INR in Telmisartan and Amlodipine group respectively. Hence the cost incurred in treating hypertension was markedly lower with the Amlodipine group as compared to the Telmisartan group. This pharmacoeconomic evaluation study shows that Amlodipine is more cost-effective as compared to Telmisartan when the cost per mm Hg reduction in SBP and DBP were considered. In India the cost of drug is a significant factor to patient compliance, cost-effective therapy of hypertension is most importance. Keywords: Pharmacoeconomics, Telmisartan, Amlodipine, Post-menopausal women, Cost effectiveness
Publication date: 01/11/2021

https://ijbpas.com/pdf/2021/November/MS_IJBPAS_2021_NOV_SPCL1007.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.11.1007